1import{j as e}from"./index-BFAQ-pcv.js";import{P as t}from"./PipelineProfilePage-Pb-r1JPY.js";import"./vendor-icons-Cmxhy9_c.js";import"./button-Ds_Km4Tx.js";import"./input-DTlad_nQ.js";const n=()=>e.jsx(t,{path:"/vk2735",name:"VK2735",eyebrow:"Pipeline compound",developer:"Viking Therapeutics",aliases:["VK-2735"],waitlistSku:"vk2735",metaTitle:"VK2735: Dual GLP-1/GIP Receptor Agonist Research Profile | Peptx",metaDescription:"VK2735 research profile: dual GLP-1 and GIP receptor agonist pharmacology, Viking Therapeutics clinical programme status, and cited published statements. Not currently stocked.",summary:"VK2735 is an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, developed by Viking Therapeutics. It has no marketing authorisation in any territory. This profile summarises receptor mechanism and clinical-register status, with published statements reproduced as attributed quotations.",mechanism:["GLP-1 and GIP are the two principal incretin hormones. Their receptors, GLP-1R and GIPR, are class B G-protein-coupled receptors that couple to Gs and adenylate cyclase, and both are expressed in pancreatic islets as well as in central and peripheral tissues. A dual agonist is a single molecule engineered to recruit both receptors rather than one.","VK2735 is described in the peer-reviewed literature as a GLP-1/GIP receptor dual agonist. Mechanistically it therefore sits in the same receptor pairing as tirzepatide, and in a different pairing from oxyntomodulin-based GLP-1/glucagon dual agonists such as mazdutide, or from triple agonists that add glucagon receptor activity.","Viking Therapeutics has reported development of both a subcutaneous and an oral formulation. Formulation route affects exposure and absorption characteristics; it does not change the receptor targets."],status:["Investigational. VK2735 is not approved in the United Kingdom, European Union or United States.","Phase 2 subcutaneous data from the VENTURE study were published in the peer-reviewed journal Obesity in 2026.","Viking Therapeutics has publicly described a Phase 3 programme (VANQUISH) for the subcutaneous formulation and continued Phase 2 work on the oral formulation. Registry entries are searchable on ClinicalTrials.gov."],quotes:[{text:"This study aimed to determine doses of VK2735, a novel glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.",attribution:"Bays HE, et al. VENTURE Phase 2 trial report. Obesity (Silver Spring). 2026;34(3):537-549. doi:10.1002/oby.70106."}],citations:[{label:"Bays HE, et al. Weekly subcutaneous VK2735 in adults with obesity (VENTURE), Phase 2. Obesity (Silver Spring). 2026;34(3):537-549. doi:10.1002/oby.70106.",url:"https://doi.org/10.1002/oby.70106"},{label:"Viking Therapeutics pipeline: VK2735.",url:"https://www.vikingtherapeutics.com/pipeline/"},{label:"ClinicalTrials.gov registry search: VK2735.",url:"https://clinicaltrials.gov/search?intr=VK2735"}],faqs:[{q:"What is VK2735?",a:"VK2735 is an investigational dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics, studied in both subcutaneous and oral formulations."},{q:"How does VK2735 differ from mazdutide?",a:"VK2735 pairs GLP-1 receptor activity with GIP receptor activity. Mazdutide pairs GLP-1 receptor activity with glucagon receptor activity. They are different receptor combinations."},{q:"Is VK2735 approved anywhere?",a:"No. It is an investigational compound with no marketing authorisation in the United Kingdom, European Union or United States."},{q:"Does Peptx supply VK2735?",a:"No. VK2735 is not currently stocked. You can register an email address on this page to be notified if verified reference material becomes available."}],related:[{label:"VK2735 Phase 3 VANQUISH research guide",to:"/blog/vk2735-viking-therapeutics-phase-3-vanquish-research-guide"},{label:"Tirzepatide profile",to:"/peptides/tirzepatide"},{label:"Mazdutide profile",to:"/peptides/mazdutide"}]});export{n as default};
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.